Working… Menu
Trial record 1 of 1 for:    NCT00640809
Previous Study | Return to List | Next Study

Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00640809
Recruitment Status : Completed
First Posted : March 21, 2008
Last Update Posted : February 2, 2021
Information provided by (Responsible Party):
Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )

Brief Summary:
To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole

Condition or disease Intervention/treatment Phase
Bowel Diseases, Inflammatory Drug: Celecoxib Other: Placebo Drug: Ibuprofen plus Omeprazole Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 408 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD)
Study Start Date : October 2003
Actual Study Completion Date : April 2004

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: A Drug: Celecoxib
200 mg oral capsule twice daily for 2 weeks

Placebo Comparator: B Other: Placebo
Matched placebo for 2 weeks

Active Comparator: C Drug: Ibuprofen plus Omeprazole
ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks

Primary Outcome Measures :
  1. Number of mucosal breaks in the small bowel for each subject [ Time Frame: Day 30 ]

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: Day 30 ]
  2. Laboratory tests [ Time Frame: Day 30 ]
  3. Vital signs [ Time Frame: Day 30 ]
  4. Correlation of number of mucosal breaks in the small bowel for each patient with the result of the fecal calprotectin test [ Time Frame: Day 30 ]
  5. Percentage of subjects with gastric mucosal breaks and the number of mucosal breaks [ Time Frame: Day 30 ]
  6. Change from screening visit in hemoglobin and hematocrit [ Time Frame: Day 30 ]
  7. Correlation of the number of gastric mucosal breaks with the number of small bowel mucosal breaks [ Time Frame: Day 30 ]
  8. Physical examination [ Time Frame: Day 30 ]
  9. Percentage of subjects with >=1 mucosal breaks [ Time Frame: Day 30 ]
  10. Total number of small bowel lesions with or without hemorrhage [ Time Frame: Day 30 ]
  11. Percentage of subjects with visible blood in the small bowel (without visualized lesions in the small bowel) [ Time Frame: Day 30 ]
  12. Change in Patient General Questionnaire Visual Analog Scale from Day 16 [ Time Frame: Day 30 ]
  13. Change in Severity of Dyspepsia Assessment questionnaire from Day 16 [ Time Frame: Day 30 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Inclusion criteria:

  • Normal, healthy gastrointestinal tract (no small bowel mucosal breaks at Day 14 according to endoscopic data
  • No history of GI ulcers, bleeding or surgery, or complete or partial stenosis of the small intestine
  • Willing not to drink any alcohol during study period

Exclusion Criteria:

Exclusion criteria:

  • Has established delayed gastric emptying or diabetic gastroparesis
  • Has active gastroesophageal reflux disease or requires anti-ulcer medications
  • Has taken aspirin or nonsteroidal antinflammatory drugs (ibuprofen, naproxen) more than 3 times per week within 2 weeks prior to the screening visit; aspirin for cardiovascular prophylaxis is restricted

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00640809

Layout table for location information
United States, Arizona
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85259
United States, California
Pfizer Investigational Site
La Jolla, California, United States, 92037
Pfizer Investigational Site
Los Angeles, California, United States, 90033
Pfizer Investigational Site
Los Angeles, California, United States, 90073
United States, Florida
Pfizer Investigational Site
Jupiter, Florida, United States, 33458
Pfizer Investigational Site
Miami, Florida, United States, 33173
United States, Illinois
Pfizer Investigational Site
Chicago, Illinois, United States, 60612
Pfizer Investigational Site
Rockford, Illinois, United States, 61107
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109-0362
United States, New York
Pfizer Investigational Site
New York, New York, United States, 10021
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97239
United States, Tennessee
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232-5280
Sponsors and Collaborators
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. Identifier: NCT00640809    
Other Study ID Numbers: A3191071
First Posted: March 21, 2008    Key Record Dates
Last Update Posted: February 2, 2021
Last Verified: January 2021
Keywords provided by Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ):
Bowel Disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Intestinal Diseases
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cyclooxygenase 2 Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors